HALEON PLC (HLN)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$9.60-2.64%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Warn: Primary pillar under pressure — no major product recalls or regulatory setbacks: 1 nationwide recall vs 0 allowed.
Haleon grows sales by expanding in South Asia with a new factory. Revenue is expected near $11.4 billion in 2026 and $11.9 billion in 2027. The company has strong brands like Sensodyne and Panadol. Earnings per share should rise from $0.55 to $0.61 next year.
A recent nationwide recall of a key product could hurt sales and brand trust. Analyst estimates have been revised down recently. Growth and earnings could stall or decline if regulatory issues persist.
The market has no clear consensus revenue growth or valuation priced in due to limited data. Analyst EPS estimates are stable but slightly lowered. Our view cautiously expects moderate growth but watches regulatory risks closely.
Breaks if: EPS falls below $0.55 in FY27
Breaks if: manufacturing unit not operational by end 2026
Breaks if: any new nationwide recall or regulatory warning
Breaks if: YoY revenue growth falls below 3% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a cyclical play within the healthcare sector. The current thesis state is marked by low confidence due to recent earnings misses and uncertain fundamentals.
Valuation appears to reflect a moderate risk profile, with the market likely pricing in some level of sector support. However, the recent performance history suggests that expectations may not fully account for potential downside risks.
Fundamentals may struggle in the near term, given the company's track record of consecutive earnings misses. The recent sector context has improved, but HLN's execution remains a concern.
The future trajectory hinges on broader sector performance, particularly the results of key competitors like TEVA, ZTS, and VTRS. If these companies continue to perform well, it could provide a lift for HLN; however, any negative shifts could exacerbate existing challenges.
Over the next 1 to 3 years, HLN's performance will depend heavily on sector dynamics and its ability to improve execution. Not investment advice.
The most important moves since the prior daily snapshot.
Our read has strengthened. It is supported by analyst_valuation.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.